aTyr Pharma to present data from tRNA synthetase candidate ATYR0101

aTyr Pharma announced that Leslie A. Nangle, Ph.D., Vice President, Research, will present findings from its platform in an oral presentation and poster at the Keystone Symposia on Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies, which is scheduled to take place March 19 – 23 in Banff, Alberta, Canada. aTyr will present findings from its innovative tRNA synthetase platform that highlight ATYR0101, a potential therapeutic biologic based on a domain appended to Aspartyl-tRNA Synthetase that is naturally occurring and selected through evolutionary intelligence to be released from cells to modulate extracellular signaling. ATYR0101 was found to bind to human fibroblasts and extracellular matrix deposited by fibroblasts via novel binding of latent transforming growth factor beta binding protein 1. LTBP1 is an extracellular matrix protein and key regulator of transforming growth factor beta, a central player in the pathogenesis of fibrotic diseases. These findings indicate that ATYR0101 may have therapeutic potential in fibrotic pathologies.